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Expression of AKR1C3 and CNN3 as markers for detection 
of lymph node metastases in colorectal cancer 
 
 
Abstract 
 
The aim of the study was to identify a set of discriminating genes that could be used for the 
prediction of Lymph node (LN) metastasis in human colorectal cancer (CRC), and for this, we 
compared the whole genome profiles of two CRC cell lines (the primary cell line SW480 and its 
LN metastatic variant, SW620) and identified eight genes [S100 calcium-binding protein P; 
aldo-keto reductase family 1(AKR1), member B1 (aldose reductase; AKR1B1); AKR1, member 
C3 (AKR1C3); calponin 3, acidic; metastasis associated in colon cancer 1; hemoglobin, epsilon 
1; trefoil factor 3; and FGGY carbohydrate kinase domain containing]. These genes were 
examined by quantitative RT-PCR in tissues and LNs in 14 CRC patients and 11 control patients. 
The level of AKR1C3 mRNA expression was significantly different between the Dukes’ stage A, 
B, and C groups and the control group (p < 0.05, p < 0.001, and p < 0.001), and was also 
significantly different between Dukes’ stage C and A or B groups (p < 0.05 and p < 0.001 
respectively). The expression of CNN3 was significantly different between the Dukes’ stage C 
and B or control groups (p < 0.001 and p < 0.01, respectively).There were significant 
correlations between the expression levels of AKR1C3 and CNN3. AKR1C3 and CNN3 
expressions are more accurate and suitable markers for the diagnosis of LN metastasis than the 
other six genes examined in this study.  
 
Keywords: AKR1C3; CNN3; lymph node metastasis; colorectal cancer; real-time 
quantitative PCR 
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Background 
 
Lymph node (LN) evaluation is an 
important factor for determining 
prognosis in colorectal cancer (CRC). LN 
metastases cause recurrence of CRC and 
are related to prognosis and survival [1]. 
Carcinoembryonic antigen (CEA) was 
first described as a gastrointestinal 
oncofetal antigen and is now known to be 
overexpressed in most carcinomas [2]. 
CEA is generally used for the detection of 
LN metastases in CRC [3, 4]. Detection 
of cytokeratin-20 by RT-PCR in 
peritumoral, histopathologic, tumor-free 
LNs is an independent prognostic factor 
for overall survival in CRC [5]. A 
biomarker for identifying patients at high 
risk of metastasis could have extensively 
clinical applications. Recent evidence 
indicates that CXC Chemokine Ligand 10 
(CXCL10), an interferon-inducible 
protein, is downregulated in recurrent 
CRC. Detection of CXCL10 as a 
prognostic marker for advanced stage 
CRC patients may help predict clinical 
outcomes [6]. Our recent study suggests 
that the expression of the E74-like factor 
3 gene (ELF3) in LNs signals the 
possibility of metastases and that ELF3 
may be more suitable than CEA as a gene 
marker for the detection of LN metastases 
from CRC [7].  
In the present study, we compared the 
whole genome profiles of two isogenic 
CRC cell lines (the primary cell line 
SW480 and its LN metastatic variant, 
SW620) to identify a set of 
discriminating genes that could be used 
for the prediction of metastasis in human 
CRC. A total of 54,359 genes in SW480 
and SW620 cells were analyzed using the 
Whole Genome Bioarray. As a result, we 
identified 8 genes that had a fivefold 
increase in the intensity ratio in SW620 
cells as compared with SW480 cells and 
examined by quantitative RT-PCR 
(qRT-PCR) in tissues and LNs in 14 CRC 
patients and 11 control patients. The 
genes selected for examination were 
S100 calcium-binding protein P (S100P); 
aldo-keto reductase family 1 (AKR1), 
member B1 (aldose reductase; AKR1B1); 
AKR1, member C3 (AKR1C3); calponin 
3, acidic (CNN3); metastasis associated 
in colon cancer 1 (MACC1); hemoglobin, 
epsilon 1 (HBE1); trefoil factor 3 
(intestinal; TFF3); and FGGY 
carbohydrate kinase domain containing 
(FGGY). S100P is known to regulate the 
cellular processes, such as cell cycle 
progression and differentiation [8, 9]. The 
protein encoded by AKR1B1 catalyzes the 
reduction of a number of aldehydes, 
including the aldehyde form of glucose, 
and the protein encoded by AKR1C3 
catalyzes the conversion of aldehydes and 
ketones [10, 11]. The protein encoded by 
CNN3 regulates actin cytoskeleton 
rearrangement, which is needed for the 
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plasma trophoblasts membranes to 
become fusion competent [12]. MACC1 
is more frequently expressed in advanced 
CRC [13]. HBE1 is normally expressed 
in adult hemoglobin and the leading 
known cause of a β-thalassemia with 
gene mutation in Southeast Asia [14]. 
TFF3 is expressed in goblet cells in the 
intestines and the colon, and 
overexpression of TFF3 after 
chemoradiotherapy for rectal cancer is 
associated with a higher risk of relapse 
[15]. FGGY encodes a member of the 
FGGY kinase family that acts as a 
phosphotransferase [16]. In this study, we 
investigated whether these genes could be 
used as biomarkers for detecting LN 
metastases of CRC by qRT-PCR. 
 
 
Materials and Methods  
 
Microarray analyses 
A total of 54,359 genes in two isogenic 
CRC cell lines (the primary cell line 
SW480 and its LN metastatic variant, 
SW620) were analyzed using a 
CodeLink™  Human  Whole Genome  
 
 
 
 
 
 
 
Bioarray (Applied Microarrays, Inc. 
Tempe, AZ, USA). We entrusted 
microarray analyses to Filgen, Inc. 
(Nagoya, Japan). The procedure was 
identical to that of a previous study [17]. 
Thirty-five genes with a fivefold increase 
in the intensity ratio in SW620 cells 
compared with SW480 were arbitrarily 
defined as being overexpressed in SW620 
cells (data not shown). Of the 35 genes 
that were overexpressed, we selected 
eight genes (S100P, AKR1C3, CNN3, 
AKR1B1, MACC1, HBE1, TFF3, and 
FGGY) that were extremely 
overexpressed and were unlikely to be 
related to inflammation in Table 1.  
 
Patients 
Twenty-seven tissue specimens (14 tumor 
specimens and 13 non-tumor specimens) 
and 125 LNs were dissected from 14 
patients with CRC. Non-tumor specimens 
were located far from primary cancer and 
confirmed not including tumor cells 
pathologically. Eleven inflammatory 
tissue specimens and 35 LNs were 
dissected as controls from 11 patients 
who were  undergoing  surgery  for  
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ulcerative colitis (UC). LNs and tissue 
specimens were obtained from surgical 
resections performed in the Department 
of Surgery, Hyogo College of Medicine, 
Nishinomiya, Japan between September, 
2009 and March, 2010. The study design 
was approved by the Ethics Review 
Committee on Genetic and Genomic 
Research, Kobe University Graduate 
School of Health Sciences, Kobe, Japan. 
Sections of formalin-fixed, 
paraffin-embedded LNs were examined 
using hematoxylin-eosin staining (HES) 
in the Department of Surgical Pathology, 
Hyogo Collage of Medicine. All LNs 
from CRC patients were categorized 
according to Dukes’ staging system [18]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Table 2). The patients were categorized 
into three groups: A (n=2), B (n= 4) and 
C (n=8). Almost all cases had lymphatic 
invasion and/or venous invasion 
regardless of LN metastasis. In almost all 
cases, invasion reached the subserosa. 
Routine HES diagnosis of LNs detected 
metastasis in 4 (28.6%) out of 14 patients, 
lymphatic invasion in 10 (71.4%), and 
venous invasion in 13 (92.9%). 
Extramural cancer deposits (EX) were 
detected in three cases. EX were defined 
as cancer foci that were not adjacent to 
the primary tumor and not associated 
with LN [19]. Case 10 was EX-positive 
diagnosed with metastasis- negative LNs 
on conventional pathologic of staging. 
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Tissue preparation / RNA extraction and 
cDNA synthesis  
Tissue preparation, RNA extraction, and 
cDNA synthesis performed in the same 
way as described in the previous report 
[7]. Each RNA from the tissues and LNs 
was standardized equal concentration. 
 
Real-time qRT-PCR 
One microliter of cDNA was used as the 
template in the reaction mixture for 
real-time qRT-PCR. For determination of 
specific gene expression, each primer was 
designed with Perfect real time primer 
(Takara, Ohtsu, Japan). The primers for 
S100P (GenBank Acc. No. NM_005980), 
AKR1C3 (GenBank Acc. No. 
NM_003739), CNN3 (GenBank Acc. No. 
NM_001839), AKR1B1 (GenBank Acc. 
No. NM_001628), MACC1 (GenBank 
Acc. No. NM_182762), HBE1 (GenBank 
Acc. No. NM_005330), TFF3 (GenBank 
Acc. No. NM_003226), FGGY (GenBank 
Acc. No. NM_018291), and β-actin 
(ACTB; GenBank Acc. No. NM_001101) 
are listed in Tables 1 and 3. The 
parameter threshold cycle (Ct) was used 
as the cycle number to detect the 
fluorescence increasing. The 
housekeeping gene ACTB was used to 
calculate the relative level of expression 
for each gene and data normalization to 
correct RNA quality and quantity using 
the 2-ΔΔCt method. qRT-PCR was 
performed on a MyiQ Real-time PCR 
System (Bio-Rad, Hercules, CA, USA) 
using SsoFast EvaGreen Supermix 
(Bio-Rad, Hercules, CA, USA) according 
to the manufacturer’s recommendations. 
The protocol was as follows: initial 
denaturation at 95°C for 30 s, followed 
by 40 cycles of denaturation at 95°C for 5 
s, annealing at the temperature suitable 
for each gene marker for 10 or 20 s, and 
extension at 72°C for 10 s (Table 3). Each 
sample was assayed in duplicate. A 
control and two references were included 
in every run to confirm each examination.  
 
Statistical analysis 
Statistical analysis was performed using 
PASW for Windows version 17.0 (SPSS 
Japan Inc., Tokyo, Japan). To set cutoff 
values for each gene marker, receiver 
operating characteristic (ROC) curve 
analysis was performed by plotting the 
true-positive fraction (sensitivity) and 
false-positive fraction (specificity) pairs 
with area under the curve (AUC) values 
for LNs dichotomized according to LN 
metastasis diagnosed by HES [20,21]. 
Data were evaluated using the Kruskal–
Wallis test, followed by the Mann–
Whitney U test with a Bonferroni 
correction. Analyses of correlations 
between levels of different mRNA 
species were performed using a 
two-tailed Spearman’s rank correlation 
test. Differences were considered as 
statistically significant at p < 0.05.   
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Results 
 
Genes with a fivefold increase in the 
intensity ratio in SW620 cells as 
compared with SW480 cells were 
arbitrarily defined as being overexpressed. 
Eight candidate genes, S100P, AKR1C3, 
CNN3, AKR1B1, MACC1, HBE1, TFF3, 
and FGGY, were selected on the basis of 
their remarkable overexpression in 
SW620 cells and unlikable to be related 
to inflammation (Table 1). We were 
examined these genes in tissues and LNs 
of 14 colorectal cancer patients and 11 
controls by real-time qRT-PCR.  
qRT-PCR was performed to quantify 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
these genes in tumor tissues (n = 14), 
non-tumor tissues from CRC patients  
(n = 13), and inflammatory tissues from 
patients with UC; the latter tissues served 
as the controls (n = 11). The results are 
shown in Fig. 1. There were no 
significant differences in the relative 
levels of mRNA expression for S100P, 
AKR1C3, CNN3, AKR1B1, HBE1, and 
TFF3 among tumor tissues, non-tumor 
tissues, and inflammatory tissues. For 
MACC1, there were significant 
differences in levels of expression 
between tumor tissues (Mean±SD, 
145.37±289.74),   non-tumor tissues  
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Figure 1. Relative mRNA expression of S100P, AKR1C3, CNN3, AKR1B1, MACC1, HBE1, TFF3, and FGGY in 
tissues from colorectal cancer (CRC) patients determined by real-time quantitative RT-PCR. Dots showed 
mRNA levels in 13 non-tumor tissues and 14 tumor tissues from CRC patients compared with 11 inflammatory tissues 
from ulcerative colitis patients as controls. Bars showed means. A: The relative quantity values (Means±SD) of S100P 
are 28.68±24.20, 14.43±12.90 and 199.51±549.78 (control, non-tumor and tumor). B: Those of AKR1C3 are 2.15±3.55 
and 0.96±1.63. C: Those of CNN3 are 2.86±1.53, 10.44±16.20 and 6.93±10.30. D: Those of AKR1B1 are 1.32±1.57, E: 
Those of MACC1 are 10.04±6.12, 69.13±158.41 and 145.37±289.74. F: Those of HBE are 0.89±1.43, 0.55±1.15 and 
0.67±1.61. G: Those of TFF3 are 154.79±216.76, 1116.46±1610.72 and 908.91±1158.59. H: Those of FGGY are 
1.02±0.50, 13.30±25.12 and 30.65±49.14, respectively. The p-values are based on Kruskal-Wallis test. +p<0.05 and  
* p<0.01 are based on Mann-Whitney U test with Bonferroni correction.  
 
21.09±26.93, 214.87±291.55 and 124.88±266.74. 
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(Mean±SD, 69.13±158.41), and 
inflammatory tissues (Mean±SD, 
10.04±6.12) (Kruskal-Wallis test;      
p < 0.05). MACC1 mRNA expression 
was significantly different between tumor 
and inflammatory tissues (Mann–
Whitney U test with a Bonferroni 
correction; p < 0.05). For FGGY, there 
were significant differences in levels of 
expression between tumor tissues 
(Mean±SD,  30.65±49.14), non-tumor 
tissues (Mean±SD, 13.30±25.12), and 
inflammatory tissues (Mean±SD, 
1.02±0.50) (Kruskal-Wallis test;       
p < 0.001). A subsequent Mann–Whitney 
U test with a Bonferroni correction 
showed that the mean values for FGGY 
expression were significantly different 
between non-tumor and inflammatory 
tissues (p < 0.05) and between tumor and 
inflammatory tissues (p < 0.01).  
To determine the cutoff values for use 
in qRT-PCR, ROC curve analysis was 
performed using relative gene expression 
values from LNs from CRC patients 
categorized according to the degree of 
LN metastasis as evaluated by HES. The 
cutoff values are shown in Table 4. The 
AUC values were as follows: CNN3 = 
0.951, SE = 0.037, 95% confidence 
interval (CI) = 0.000–1.000, p = 0.00002; 
and AKR1C3 = 0.919, SE = 0.043, 95% 
CI = 0.829–1.000, p = 0.00008. The 
cutoff values for CNN3 and AKR1C3 
were set at 18.31 with 87.5% sensitivity 
and 96.6% specificity rates, and 56.74 
with 87.5% sensitivity and 93.2% 
specificity rates, respectively. The AUC 
values of the other six genes were below 
0.9.  
To investigate whether each gene was 
overexpressed in metastatic LNs from 
CRC, we measured mRNA expression in 
12 LNs from patients categorized into 
Dukes’ stage A, 97 LNs from patients 
categorized into Dukes’ stage B, and 16 
LNs from Dukes’ stage C. As a control, 
we also measured mRNA expression in 
35 LNs dissected from UC patients. As 
shown in Fig. 2, each level of S100P, 
AKR1C3, CNN3 , AKR1B1, MACC1 and 
HBE1 mRNA expression was signif- 
icantly different among the Dukes’ stage 
A, B, and C groups and the control group 
(S100P, AKR1C3, CNN3: p < 0.001, ; 
AKR1B1, MACC1, HBE1: p < 0.01, 
respectively; Kruskal–Wallis test). The 
level of AKR1C3 mRNA expression was 
significantly different between the Dukes’ 
stage A, B, and C groups and the control 
group (p < 0.05, p < 0.001, and p < 0.001, 
respectively; Mann–Whitney U test with 
a Bonferroni correction), and was also 
significantly different between Dukes’ 
stage C and Dukes’ stage A or Dukes’ 
stage B groups (p < 0.05 and p < 0.001 
respectively). A subsequent Mann–
Whitney U test with a Bonferroni 
correction showed that expression of 
CNN3  and  MACC1 was significantly  
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Figure 2. Relative mRNA 
expression of S100P, AKR1C3, 
CNN3, AKR1B1, MACC1, HBE1, 
TFF3, and FGGY in lymph nodes 
(LNs) from colorectal cancer 
(CRC) patients categorized by 
Duke’s classification. Dots 
showed mRNA levels in 125 LNs 
from CRC patients with Dukes’ 
stage A, B and C, compared with 
35 LNs from ulcerative colitis  
patients as controls. Black dots 
indicate LNs with tumor cells, and 
grey dots indicate LNs without 
tumor cells identified by 
hematoxylin–eosin staining. 
Broken lines show cut-off values 
of eight genes in Table 4. Bars 
showed means. A: The relative 
quantity values (Means±SD) of 
S100P are 53.17±208.51, 
1.30±2.86, 1.10±6.44 and 
6.24±16.00 (control, Dukes’ A, 
Dukes’ B and Dukes’ C). B: Those 
of AKR1C3 are 1.97±3.14, 
13.99±17.82, 34.03±201.50 and 
87.72±127.72. C: Those of CNN3 
are 5.46±6.73, 5.73±5.28, 
4.06±6.39 and 22.97±26.78.  D: 
Those of AKR1B1 are 5.49±7.29, 
3.44±2.72, 5.15±15.99 and 
3.64±4.01. E: Those of MACC1 
are 4.53±6.06, 10.87±10.81, 
6.43±18.75 and 34.17±95.53.   
F: Those of HBE are 8.57±22.92, 
1.61±4.06, 0.48±1.14 and 
5.52±9.51. G: Those of TFF3 are 
7.75±13.53, 13.54±25.01, 
5.48±16.74 and 16.70±43.65.  
H: Those of FGGY are 6.45±14.38,    
3.67±2.87, 3.20±5.24 and 
4.41±4.33, respectively. The 
p-values are based on 
Kruskal-Wallis test. +p<0.05,  
* p<0.01 and ** p<0.001 are based 
on Mann-Whitney U test with 
Bonferroni correction. 
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different between the Dukes’ stage B 
and C groups (p < 0.001, p < 0.01, 
respectively), and between the control 
and the Dukes’ stage C groups      
(p < 0.01, p < 0.05, respectively). The 
S100P and HBE1 was significantly 
different between the Dukes’ stage B 
and C groups (p < 0.001, p < 0.001, 
respectively), and the S100P and 
AKR1B1 was significantly different 
between the control and the Dukes’ 
stage B groups (p < 0.001, p < 0.05, 
respectively). On the other hand, there 
were no significant differences in 
TFF3 and FGGY mRNA expression 
among those four groups. The mRNA 
expression of AKR1C3, CNN3, and 
MACC1 was significantly higher in the 
Dukes’ stage C group than in the 
control group.  
Furthermore, to investigate the 
correlation between the mRNA levels 
for the eight biomarkers, we compared 
mRNA expression in the LNs of CRC 
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patients and controls. LNs from the 
controls and each staging group were 
analyzed separately. The results worthy 
of special mention are shown in  
Table 5. There were significant 
correlations between the levels of 
AKR1C3 and CNN3 mRNA expression 
overall (r = 0.635; p < 0.001), in Dukes’ 
A (r = 0.888; p < 0.001), Dukes’ B   
(r = 0.712; p < 0.001) and Dukes’ C  
(r = 0.844; p < 0.001) groups, and in 
the control group (r = 0.475; p < 0.01). 
The relationships between the 
qRT-PCR results and histological 
examination are shown in Table 6. The 
results can be summarized as follows: 
there were 7 of 7 true-positives for 
S100P, AKR1C3, CNN3, AKR1B1, and 
HBE1; 6 of 7 for MACC1; 5 of 7 for 
TFF3; and 3 of 7 for FGGY (statistical 
analysis was omitted due to low case 
numbers). 
 
 
Discussion  
 
Recently, there have been many reports 
regarding the use of novel gene 
markers to detect colon tumors in early 
stages and diagnose the status of the 
disease appropriately. The purpose of 
this study was to find new markers for 
the detection of LN metastases in CRC 
by qRT-PCR. On the basis of 
comparative microarray analyses, we 
identified eight candidate genes 
(S100P, AKR1C3, CNN3, AKR1B1, 
MACC1, HBE1, TFF3, and FGGY).  
In this study, S100P was remarkably 
overexpressed in SW620 cells as 
compared with SW480 (intensity ratio 
= 48.41). It has been reported that 
expression of the S100P mRNA and 
protein is significantly higher in 
cancerous regions than in 
non-cancerous tissues [22]. It has been 
known to express in cancer cells in 
adult specifically and to mediate tumor 
growth, drug resistance, and metastasis 
[23-25]. However, our study revealed 
that there are no significant differences 
in levels of S100P expression between 
non-tumor tissues and tumor tissues. 
Our findings conflict with those 
reported by others. 
As a result of our ROC curve 
analysis, we conclude that AKR1C3 
and CNN3 expression are more 
accurate and suitable for the diagnosis 
of LN metastasis than the other 6 genes. 
The AUC values of AKR1C3 and 
CNN3 were 0.919 and 0.951, 
respectively, whereas our previous data 
showed AUC values for ELF3 and 
CEA of 0.955 and 0.903, respectively 
[7]. From this point of view, AKR1C3 
and CNN3 are more accurate markers 
than CEA and may be considered to be 
as accurate as ELF3. 
The mRNA expressions of AKR1C3 
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and CNN3 were found to be 
significantly higher in the Dukes’ stage 
C group than in the control groups. The 
AKR1C3 mRNA expression was also 
found to be significantly different 
between the Dukes’ stage C group and 
the other Dukes’ groups. To our 
knowledge, this report is the first study 
on LN metastasis in CRC that has 
focused on AKR1C3 and CNN3. We 
found that the mRNA expression of 
both genes in primary tumor tissues 
was different from that in non-tumor or 
inflammatory tissues. In addition, there 
was a significant correlation between 
AKR1C3 and CNN3 mRNA expression 
(Table 5).  AKR1C3 expression has 
been demonstrated in sex 
hormone-dependent tissues, including 
breast [11], endometrial [26], testis 
[27], and prostate tissues [11] as well 
as in sex hormone-independent tissues, 
including kidney, bladder, and 
urothelial tissues [28]. Elevated 
expression of AKR1C3 has been 
identified in prostate and breast cancer 
and is correlated with the 
aggressiveness of the disease [11, 29, 
30]. Positive immunoreactivity 
AKR1C3 was widely present in both 
adenocarcinoma and squamous cell 
carcinoma of the lung and 
gastroesophageal junction [31]. A 
previous study showed that AKR1C3 
mRNA and protein were overexpressed 
in castration-resistant prostate cancer 
tissue as compared to benign prostate 
and primary prostate cancer tissue [32]. 
CNN3 was identified the gene in 
tumorigenic parameter as ovarian 
cancer and mucosa-associated 
lymphoid tissue lymphoma [33, 34]. 
MACC1 is a key regulator of the 
hepatocyte growth factor receptor 
pathway, including in cellular growth, 
invasiveness, and metastasis, and is 
useful to identify the poor prognosis in 
CRC patients [35]. We found that the 
level of MACC1 mRNA expression 
differs between primary tumor tissues 
and inflammatory tissues (p < 0.05, 
Kruskal–Wallis test). As MACC1 
overexpression was not found in all the 
histologically positive LNs examined 
in this study, we conclude that MACC1 
may be inferior to AKR1C3 and CNN3 
in detecting LN metastases.  
However, AKR1B1, HBE1, TFF3, 
and FGGY were not suitable for 
detecting LN metastases in view of the 
fact that there were no significant 
differences in the expression levels of 
these genes between the control group 
and the Dukes’ stage C group. AKR1B1 
is overexpressed in human tumors, 
such as those found in liver, breast, and 
lung cancer, and may play an important 
role in the development and 
progression of cancer [36]. There is no 
previous report of HBE1’s expression 
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in cancer cells. TFF3 expression may 
play a role in promoting LN metastases 
in CRC [37]. FGGY expression has 
been recently associated with an 
increased susceptibility to sporadic 
amyotrophic lateral sclerosis [38].  We 
would like to emphasize our study 
limitations, especially the number of 
patients were not enough for definitive 
conclusion. Thus, it may be biased by 
the relatively small number of patients. 
In conclusion, AKR1C3 and CNN3 
expression are more accurate and 
suitable markers for the diagnosis of 
LN metastasis than the other six genes 
examined in this study. We found that 
the difference in AKR1C3 expression 
between all Dukes’ stage groups and 
the control group was statistically 
significant. In addition, there were 
significant correlations between the 
expression levels of AKR1C3 and 
CNN3. AKR1C3 and CNN3 might be 
more suitable than the other six genes 
as gene markers for the detection of 
LN metastases from CRC and requires 
further verification as biomarkers in a 
larger population study. 
 
 
Abbreviations 
LN Lymph node  
CRC colorectal cancer 
UC ulcerative colitis 
CEA Carcinoembryonic antigen  
CXCL10 CXC Chemokine Ligand 10  
ELF3 E74-like factor 3  
S100P S100 calcium-binding protein P 
AKR1 aldo-keto reductase family 1 
AKR1B1 AKR1, member B1  
AKR1C3 AKR1, member C3  
CNN3 calponin 3, acidic  
MACC1 metastasis associated in colon 
cancer 1 
HBE1 hemoglobin, epsilon 1  
TFF3 trefoil factor 3  
FGGY FGGY carbohydrate kinase 
domain containing.  
HES hematoxylin–eosin staining 
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